We’re experiencing issues for some mobile devices with our ARTG dataset filter function. We apologise for any inconvenience while we work to fix this.
PLUVICTO (Novartis Pharmaceuticals Australia Pty Ltd)
Product name
PLUVICTO
Date registered
Evaluation commenced
Decision date
Approval time
209 (255 working days)
Active ingredients
lutetium (177Lu) vipivotide tetraxetan
Registration type
EOI
Indication
PLUVICTO is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway inhibitor (ARPI) therapy, and:
- are considered appropriate to delay taxane-based chemotherapy, or
- have received prior taxane-based chemotherapy